24/7 Market News Snapshot 30 October, 2024 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)

October 30, 2024

DENVER, Colo., 30 October, 2024 (247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
Tiziana Life Sciences Ltd. is currently experiencing a positive trend in pre-market trading, with shares priced at $1.131, marking an increase of 10.88% from the previous close of $1.020. This rise is indicative of strong buying interest, potentially driven by favorable market sentiment or significant announcements regarding the company. With a current trading volume of 610.32K shares, active market participation reinforces the optimistic outlook for TLSA. Investors are advised to watch a critical resistance level around $1.15 while support is likely near $1.00. Monitoring volume trends and broader market conditions will be important for assessing potential reversals or continuation patterns in TLSA’s share performance.

Concurrently, Tiziana Life Sciences has announced promising preclinical outcomes from a study highlighting the anti-inflammatory properties of its lead candidate, intranasal foralumab, particularly when used in conjunction with semaglutide, a GLP-1 agonist. Conducted by a prominent research team, the study illustrates that this combination markedly improves liver health and reduces inflammation in models of diet-induced obesity. Significant reductions in inflammation markers were observed, underscoring the potential of this therapeutic strategy to combat the health challenges associated with obesity and its inflammatory consequences.

Dr. Howard L. Weiner, Chairman of Tiziana’s Scientific Advisory Board, expressed optimism regarding the combination’s potential to transform treatment options for obesity-related metabolic disorders. Co-lead researcher Dr. Selma Boulenouar highlighted the implications of these findings, suggesting that the dual therapy could be crucial in tackling chronic inflammation often accompanying obesity and liver conditions. As part of Tiziana’s commitment to innovative drug development, these results pave the way for advancing clinical trials aimed at addressing complex metabolic and inflammatory health issues.

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.